OXANAMIDE

US Previously Marketed

First approved in 1958

Details

Stereochemistry	MIXED
Molecular Formula	C8H15NO2
Molecular Weight	157.2102
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1OC1(CC)C(N)=O

InChI

InChIKey=WBLPIVIXQOFTPQ-UHFFFAOYSA-N

InChI=1S/C8H15NO2/c1-3-5-6-8(4-2,11-6)7(9)10/h6H,3-5H2,1-2H3,(H2,9,10)

HIDE SMILES / InChI

Molecular Formula	C8H15NO2
Molecular Weight	157.2102
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13638840

Oxanamide is an anxiolytic and muscle relaxant that was effective in the treatment of anxiety resulting from premenstrual syndrome, menopause. The tranquilizing effect of oxanamide was noticeable within two or three days, and improvement in nervous and emotional symptoms was soon evident. Information about the current use of this drug is not available.

Approval Year

Doses

Dose	Population	Adverse events
4.8 g multiple, oral Highest studied dose Dose: 4.8 g Route: oral Route: multiple Dose: 4.8 g Sources: https://pubmed.ncbi.nlm.nih.gov/13638840 Page: p.275	unhealthy Health Status: unhealthy Condition: Psychosis Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/13638840 Page: p.275	Sources: https://pubmed.ncbi.nlm.nih.gov/13638840 Page: p.275
800 mg 4 times / day multiple, oral (max) Studied dose Dose: 800 mg, 4 times / day Route: oral Route: multiple Dose: 800 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/13638840 Page: p.277	unhealthy n = 45 Health Status: unhealthy Condition: Anxiety Sex: F Population Size: 45 Sources: https://pubmed.ncbi.nlm.nih.gov/13638840 Page: p.277	Sources: https://pubmed.ncbi.nlm.nih.gov/13638840 Page: p.277

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L1LHH
AHH Chemical co.,ltd	MR-1013859	http://www.ahhchemical.com/product/MR-1013859.html
Chemieliva Pharmaceutical Co., Ltd	PBCM0193178
Chemspace	CSC000076872
Enamine	BBV-38278618
LGC Standards	LGCFOR3211.00	https://www.lgcstandards.com/US/en/p/LGCFOR3211.00
MuseChem	M068883
NovoSeek	31365
Smolecule	S568982	https://www.smolecule.com/products/s568982
THE BioTek	bt-374734	https://www.thebiotek.com/product/others/bt-374734
ZINC	ZINC000000000571	http://zinc15.docking.org/substances/ZINC000000000571
ZINC	ZINC000002015517	http://zinc15.docking.org/substances/ZINC000002015517
ZINC	ZINC000002015518	http://zinc15.docking.org/substances/ZINC000002015518
ZINC	ZINC000002015519	http://zinc15.docking.org/substances/ZINC000002015519

PubMed

Title	Date	PubMed
Oxanamide; adjunctive use of a new tranquilizer in gynecology.	1959 Apr	13638840
Effects of oxanamide on the central nervous system.	1960 Jan	14412594
Effects of oxanamide on anxiety during oral surgery.	1962 Mar	14007200

Sample Use Guides

In Vivo Use Guide

dosage of three tablets daily (total 1,200 mg. oxanamide), the patients were instructed to reduce the dosage or to take the drug only at bedtime.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:35:39 GMT 2023` Edited by `admin` on `Sat Dec 16 17:35:39 GMT 2023`
Record UNII	050271194T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXANAMIDE

Official Name

English

2,3-EPOXY-2-ETHYLHEXANAMIDE

Systematic Name

English

OXANAMIDE [MI]

Common Name

English

oxanamide [INN]

Common Name

English

Code System Code Type Description

DRUG CENTRAL

2010